Home  »  Science   »  Reata Pharmaceuticals Inc. (NASDAQ:RETA) Has Recov...

Reata Pharmaceuticals Inc. (NASDAQ:RETA) Has Recovered 79.44% So Far, But Another -5.74% Loss Is Possible.

Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s traded shares stood at 1.14 million during the last session, with the company’s beta value hitting 1.03. At the close of trading, the stock’s price was $89.84, to imply an increase of 3.95% or $3.41 in intraday trading. The RETA share’s 52-week high remains $95.00, putting it -5.74% down since that peak but still an impressive 79.44% since price per share fell to its 52-week low of $18.47. The company has a valuation of $3.36B, with an average of 1.53 million shares in intraday trading volume over the past 10 days and average of 1.48 million shares over the past 3 months.

Analysts have given a consensus recommendation of an Overweight for Reata Pharmaceuticals Inc. (RETA), translating to a mean rating of 1.70. Of 10 analyst(s) looking at the stock, 0 analyst(s) give RETA a Sell rating. 1 of those analysts rate the stock as Overweight while 2 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$2.21.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Reata Pharmaceuticals Inc. (NASDAQ:RETA) trade information

After registering a 3.95% upside in the last session, Reata Pharmaceuticals Inc. (RETA) has traded red over the past five days. The stock hit a weekly high of 90.79 this Thursday, 03/16/23, jumping 3.95% in its intraday price action. The 5-day price performance for the stock is 6.19%, and 111.29% over 30 days. With these gigs, the year-to-date price performance is 136.48%. Short interest in Reata Pharmaceuticals Inc. (NASDAQ:RETA) saw shorts transact 8.14 million shares and set a 16.51 days time to cover.

Analysts on Wall Street suggest a consensus price target of $112.00, implying an increase of 19.79% to the stock’s current value. The extremes give us $75.00 and $198.00 for target low and target high price respectively. As such, RETA has been trading -120.39% off suggested target high and 16.52% from its likely low.

Reata Pharmaceuticals Inc. (RETA) estimates and forecasts

Looking at statistics comparing Reata Pharmaceuticals Inc. share performance against respective industry, we note that the company has underperformed competitors. Reata Pharmaceuticals Inc. (RETA) shares are 210.76% up over the last 6 months, with its year-to-date growth rate lower than industry average at -3.17% against 9.40%. Revenue is forecast to grow 6.00% this quarter before falling -12.30% for the next one. The rating firms project that company’s revenue will shrink -77.10% compared to the previous financial year.

Revenue forecast for the current quarter as set by 7 analysts is $490k. Meanwhile, for the quarter ending Mar 2023, a total of 5 analyst(s) estimate revenue growth to $110k.Earnings reports from the last fiscal year show that sales brought in $934k and $914k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -47.50% before dropping -88.00% in the following quarter.

RETA Dividends

Reata Pharmaceuticals Inc. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Reata Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s Major holders

Reata Pharmaceuticals Inc. insiders hold 3.70% of total outstanding shares, with institutional holders owning 90.22% of the shares at 93.69% float percentage. In total, 90.22% institutions holds shares in the company, led by CPMG INC. As of Sep 29, 2022, the company held over 2.9 million shares (or 9.13% of shares), all amounting to roughly $72.8 million.

The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 2.65 million shares, or about 8.36% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $66.68 million.

We also have Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Reata Pharmaceuticals Inc. (RETA) shares. Going by data provided on Oct 30, 2022, Vanguard Specialized-Health Care Fund holds roughly 1.24 million shares. This is just over 3.90% of the total shares, with a market valuation of $39.84 million. Data from the same date shows that the other fund manager holds a little less at 0.82 million, or 2.59% of the shares, all valued at about 20.67 million.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts